Category: St. Jude Medical
Here's a look at some of the top Wall Street stories for medical device companies this week: Renal denervation isn't dead, despite Medtronic trial's failure; Baxter says HQ will stay in Illinois, stays coy on Boston plans; Private equity owners rebrand KCI, Systagenix, LifeCell as Acelity
, Apax Partners
, Baxter International
, Boston Scientific
, Centaur Guernsey
, Kinetic Concepts Inc.
, Kona Medical
, LifeCell Corp.
, ReCor Medical
, St. Jude Medical
, Systagenix Wound Management Inc.
St. Jude Medical says that its Quartet quadripolar leads "performed better than bipolar leads of any kind" in a recent mega-study.
Medical device giant St. Jude Medical (NYSE:STJ) had high praise for its own quadripolar leads, saying that blow away any competition from older bipolar leads.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Researchers report that St. Jude Medical's fractional flow reserve technology helps slash adverse events, especially urgent revascularizations, compared with medical therapy alone.
The failure of Medtronic's Symplicity 3 trial doesn't mean the end of renal denervation in treated resistant hypertension, especially in Europe, but future studies face a high bar set by the Medtronic trial's sham control arm.
A federal judge agrees to toss a lawsuit filed against Johnson & Johnson's Biosense Webster by a former sales rep and her new employer, St. Jude Medical.
St. Jude Medical says the FDA cleared a 2009 warning letter issued over a plant in Plano, Texas, that makes neuromodulation devices.